CNTX Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About CNTX Interactive Breakdown Better Bets vs. CNTX Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Context Therapeutics (CNTX)

    Market Price (10/10/2026): $0.3009 | Market Cap: $28.6 MilSector: Health Care | Industry: Biotechnology

    Context Therapeutics (CNTX)

    Market Price (10/10/2026): $0.3009
    Market Cap: $28.6 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -150%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -120%, 3Y Excs Rtn is -157%

    Penny stock
    Mkt Price is 0.3

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -49 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -166%

    High stock price volatility
    Vol 12M is 106%

    Key risks
    CNTX key risks include [1] its history of unprofitability and need for future funding, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -150%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -120%, 3Y Excs Rtn is -157%
    3 Penny stock
    Mkt Price is 0.3
    4 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    5 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -49 Mil
    6 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -166%
    7 High stock price volatility
    Vol 12M is 106%
    8 Key risks
    CNTX key risks include [1] its history of unprofitability and need for future funding, Show more.

    CNTX in ETFs

    Weight = CNTX's share of each fund

    VTI0.00%
    IWM0.00%
    IWO0.00%
    VTWO0.00%

    Valuation & Metrics

    FYE: 12/31CNTX [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$2.0 Mil—
    FY 2027 Sales$0.0 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth-100.0%13.1%
    EARNINGS
    LTM Net Income (GAAP) [3]$-46.0 Mil—
    FY 2026 Net Income (Non-GAAP)$-45.2 Mil—
    FY 2027 Net Income (Non-GAAP)$-40.8 Mil—
    FY 2027 Net Income Growth—18.9%
    FY 2026 EPS (Non-GAAP)$-0.46—
    FY 2027 EPS (Non-GAAP)$-0.43—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S14.31.7
    FY 2027 P/S——
    FY 2026 P/E—7.9
    FY 2027 P/E——

    [1] CNTX forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 10/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Product Candidates in Pipeline310282025Link
    Active Clinical Trials211052025Link
    Patients Enrolled in CTIM-76 Phase 1 Trial1211052025Link
    Patients Enrolled in CT-95 Phase 1 Trial611052025Link
    Preclinical Programs111052025Link
    Active Trial Sites for CTIM-76 Phase 1 Trial376022025Link

    Price Chart

    null
    Upcoming
    11/04/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 10/1/2026

    Context Therapeutics (CNTX) stock has lost about 45% since 6/30/2026 because of the following key factors:

    1. Continued Negative Market Reaction to CTIM-76 Interim Clinical Trial Data.

    Despite Context Therapeutics announcing "positive interim efficacy and safety results" from the Phase 1 clinical trial for CTIM-76 on June 15, 2026 (fiscal Q2 2026), the stock experienced a significant decline of over 51% within 24 hours. This market reaction, stemming from investor expectations that were considerably higher or the results not being robust enough, initiated a sharp downward trend that continued into the subsequent fiscal quarter, contributing to the stock's overall loss.

    2. Fiscal Q2 2026 Earnings Miss and Widening Net Loss.

    On August 5, 2026 (fiscal Q3 2026), Context Therapeutics reported its fiscal Q2 2026 financial results (for the period ending June 30, 2026). The company announced a net loss of $14.6 million, which was significantly wider than the $8.8 million loss reported in fiscal Q2 2025. The Earnings Per Share (EPS) of -$0.15 missed the consensus estimate of -$0.09 by $0.06, leading to a 27.27% drop in the stock price on August 6, 2026.

    Show more
    Updated on 10/1/2026

    Context Therapeutics (CNTX) stock has lost about 45% since 6/30/2026 because of the following key factors:

    1. Continued Negative Market Reaction to CTIM-76 Interim Clinical Trial Data.

    Despite Context Therapeutics announcing "positive interim efficacy and safety results" from the Phase 1 clinical trial for CTIM-76 on June 15, 2026 (fiscal Q2 2026), the stock experienced a significant decline of over 51% within 24 hours. This market reaction, stemming from investor expectations that were considerably higher or the results not being robust enough, initiated a sharp downward trend that continued into the subsequent fiscal quarter, contributing to the stock's overall loss.

    2. Fiscal Q2 2026 Earnings Miss and Widening Net Loss.

    On August 5, 2026 (fiscal Q3 2026), Context Therapeutics reported its fiscal Q2 2026 financial results (for the period ending June 30, 2026). The company announced a net loss of $14.6 million, which was significantly wider than the $8.8 million loss reported in fiscal Q2 2025. The Earnings Per Share (EPS) of -$0.15 missed the consensus estimate of -$0.09 by $0.06, leading to a 27.27% drop in the stock price on August 6, 2026.

    3. Nasdaq Minimum Bid Price Non-Compliance.

    Context Therapeutics received a written notice from Nasdaq on July 29, 2026 (fiscal Q3 2026), indicating non-compliance with the Minimum Bid Price Rule. This rule requires a closing bid price of at least $1.00 for 30 consecutive business days. The notice signals potential delisting concerns and financial instability, which typically places downward pressure on a stock.

    4. Discontinuation of the CT-95 Program.

    Concurrently with the fiscal Q2 2026 earnings report on August 5, 2026 (fiscal Q3 2026), Context Therapeutics announced the discontinuation of its CT-95 development program. This decision was made to prioritize the CTIM-76 and CT-202 programs, and the narrowing of the pipeline may have been perceived negatively by investors, contributing to the stock's decline.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -45.1% change in CNTX stock from 6/30/2026 to 10/9/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).
    (LTM values as of)630202610092026Change
    Stock Price ($)0.550.30-45.1%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)95950.0%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    6/30/2026 to 10/9/2026
    ReturnCorrelation
    CNTX-45.1% 
    Market (SPY)4.3%8.1%
    Sector (XLV)7.7%-0.0%

    Fundamental Drivers

    The -88.4% change in CNTX stock from 3/31/2026 to 10/9/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).
    (LTM values as of)331202610092026Change
    Stock Price ($)2.620.30-88.4%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)95950.0%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    3/31/2026 to 10/9/2026
    ReturnCorrelation
    CNTX-88.4% 
    Market (SPY)20.0%3.9%
    Sector (XLV)17.0%10.2%

    Fundamental Drivers

    The -68.6% change in CNTX stock from 9/30/2025 to 10/9/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).
    (LTM values as of)930202510092026Change
    Stock Price ($)0.970.30-68.6%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)95950.0%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2025 to 10/9/2026
    ReturnCorrelation
    CNTX-68.6% 
    Market (SPY)17.8%2.8%
    Sector (XLV)24.3%3.8%

    Fundamental Drivers

    The -79.9% change in CNTX stock from 9/30/2023 to 10/9/2026 was primarily driven by a -83.2% change in the company's Shares Outstanding (Mil).
    (LTM values as of)930202310092026Change
    Stock Price ($)1.510.30-79.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1695-83.2%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2023 to 10/9/2026
    ReturnCorrelation
    CNTX-79.9% 
    Market (SPY)88.4%13.5%
    Sector (XLV)38.9%11.7%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    CNTX Return-48%-76%73%-7%40%-80%-94%
    Peers Return-15%-20%-11%0%-35%-42%-77%
    S&P 500 Return27%-19%24%23%16%13%107%

    Monthly Win Rates [3]
    CNTX Win Rate67%42%50%58%67%40% 
    Peers Win Rate46%31%44%47%47%24% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    CNTX Max Drawdown--78%-55%-63%-56%-91% 
    Peers Max Drawdown-35%-40%-49%-45%-59%-50% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: VRTX, CMND, CNSY, CNXU, CSBR.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 10/9/2026 (YTD)

    How Low Can It Go

    EventCNTXS&P 500
    2025 US Tariff Shock
      % Loss-34.4%-18.8%
      % Gain to Breakeven52.4%23.1%
      Time to Breakeven13 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-25.4%-9.5%
      % Gain to Breakeven34.0%10.5%
      Time to Breakeven23 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-42.7%-6.7%
      % Gain to Breakeven74.4%7.1%
      Time to Breakeven22 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-63.8%-24.5%
      % Gain to Breakeven176.5%32.4%
      Time to Breakeven1228 days427 days

    Compare to VRTX, CMND, CNSY, CNXU, CSBR

    In The Past

    Context Therapeutics's stock fell -34.4% during the 2025 US Tariff Shock. Such a loss loss requires a 52.4% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventCNTXS&P 500
    2025 US Tariff Shock
      % Loss-34.4%-18.8%
      % Gain to Breakeven52.4%23.1%
      Time to Breakeven13 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-25.4%-9.5%
      % Gain to Breakeven34.0%10.5%
      Time to Breakeven23 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-42.7%-6.7%
      % Gain to Breakeven74.4%7.1%
      Time to Breakeven22 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-63.8%-24.5%
      % Gain to Breakeven176.5%32.4%
      Time to Breakeven1228 days427 days

    Compare to VRTX, CMND, CNSY, CNXU, CSBR

    In The Past

    Context Therapeutics's stock fell -34.4% during the 2025 US Tariff Shock. Such a loss loss requires a 52.4% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Context Therapeutics (CNTX)

    Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various cancers affecting women. Based in Philadelphia, Pennsylvania, the company's primary goal is to address significant unmet medical needs in female hormone-dependent and gynecologic cancers, advancing potential new therapies through clinical development.

    The company's lead product candidate is onapristone extended release (ONA-XR). ONA-XR is a potent and selective antagonist of the progesterone receptor, which has been linked to resistance against other cancer treatments, such as anti-estrogen therapies. This drug is being developed to overcome such resistance in female hormone-dependent cancers, aiming to improve therapeutic effectiveness for patients.

    Context Therapeutics is also developing CLDN6xCD3 bsAb, a bispecific monoclonal antibody created in partnership with Integral Molecular, Inc. This product is designed to redirect T-cells to specifically target and destroy malignant cells expressing the Claudin 6 (CLDN6) antigen, with a particular focus on gynecologic cancer therapy. The company's primary market for these therapies is women undergoing cancer treatment in the United States.

    AI Analysis | Feedback

    1. AstraZeneca for early-stage women's cancer drugs.

    2. Genentech for novel gynecologic cancer therapies.

    AI Analysis | Feedback

    ```html
    • Onapristone extended release (ONA-XR): A progesterone receptor antagonist aimed at overcoming resistance to cancer therapeutics in female hormone-dependent cancers.
    • CLDN6xCD3 bsAb: A bispecific monoclonal antibody designed to redirect T-cell-mediated lysis against malignant cells expressing CLDN6.
    ```

    AI Analysis | Feedback

    Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on developing product candidates for the treatment of cancer. As such, the company is currently engaged in research and development and has not yet brought any products to market for commercial sale. Therefore, Context Therapeutics does not currently have major customers purchasing its products.

    AI Analysis | Feedback

    Integral Molecular, Inc.

    AI Analysis | Feedback

    Martin Lehr, Chief Executive Officer

    Mr. Lehr is the Co-founder and CEO of Context Therapeutics. He was previously part of the founding team at Osage University Partners, a venture capital fund that invested in technologies from academic universities, focusing on early-stage oncology and rare disease opportunities. Mr. Lehr conducted research at the Sloan Kettering Institute and the Children's Hospital of Philadelphia. He also serves on the Boards of Praesidia Biologics and CureDuchenne Ventures and is a Director of BioBreak.

    Jennifer Minai-Azary, Chief Financial Officer

    Ms. Minai-Azary was appointed Chief Financial Officer of Context Therapeutics in November 2021.

    Karen Chagin, MD, Chief Medical Officer

    Dr. Chagin is the Chief Medical Officer of Context Therapeutics. Before joining Context, she served as Senior Vice President of Early-Stage Development at Adaptimmune, where she played a critical role in the development and approval of Tecelra (afamitresgene autoleucel). She also held positions of increasing responsibility, culminating as Chief Medical Officer, at Tmunity from 2019 to 2023.

    Alex Levit, Esq, Chief Legal Officer

    Mr. Levit was appointed Chief Legal Officer of Context Therapeutics in April 2021.

    Christopher Beck, MBA, SVP of Operations

    Mr. Beck joined Context Therapeutics in January 2022 as SVP of Operations. He is a pharmaceutical leader with a 30-year career spanning private, public, startup, and high-growth Pharmaceutical and Biotech companies. Previously, Mr. Beck served as Vice President Program Management at Galera Therapeutics.

    AI Analysis | Feedback

    Context Therapeutics Inc. (CNTX) faces several key risks inherent to its nature as a clinical-stage biopharmaceutical company.

    1. Clinical Development and Regulatory Approval Risk: As a company primarily focused on developing novel treatments for cancer, Context Therapeutics' success hinges on the successful outcome of its ongoing clinical trials for product candidates such as CTIM-76, CT-95, and CT-202. There is a significant risk that these product candidates may fail to demonstrate efficacy or sufficient safety profiles during preclinical and clinical testing, or may not receive the necessary regulatory approvals (e.g., from the FDA) required for commercialization. Such failures would materially and adversely affect the company's business, financial condition, and prospects.
    2. Funding and Capital Requirements Risk: Context Therapeutics is a clinical-stage company with a limited operating history and no products currently generating revenue from sales. Consequently, the company is highly dependent on raising substantial additional capital to fund its research and development activities, conduct clinical trials, and support its operations through to potential commercialization. While the company has reported a cash runway extending into 2027, it will require significant future financing. An inability to secure this additional funding on favorable terms or at all could force the company to delay, reduce, or terminate its product development programs or other business operations.
    3. Limited Operating History and Commercialization Risk: Given its status as a clinical-stage biopharmaceutical company, Context Therapeutics has a limited operating history and has not yet successfully commercialized any products or generated product sales revenue. This makes it challenging to evaluate the company's business and future prospects. Even if product candidates successfully complete clinical trials and obtain regulatory approval, there is no guarantee that the company will be able to successfully commercialize them, achieve market acceptance, build necessary sales and marketing infrastructure, or generate significant sales, all of which are crucial for sustained profitability.

    AI Analysis | Feedback

    BioNTech's CLDN6 CAR-T program (BNT211) represents a clear emerging threat. While Context Therapeutics is developing a CLDN6xCD3 bispecific antibody to target CLDN6-expressing malignant cells in gynecologic cancers, BioNTech has a CLDN6-targeted CAR-T cell therapy (BNT211) that has shown promising early clinical data in solid tumors, including ovarian cancer and testicular cancer, which fall under the relevant cancer types. CAR-T cell therapy is a distinct and potentially more potent therapeutic modality compared to bispecific antibodies for targeting specific antigens on cancer cells. If BioNTech's CLDN6 CAR-T continues to demonstrate superior efficacy or durability, it could significantly disrupt the market potential for Context Therapeutics' CLDN6 bispecific antibody program by offering a more impactful treatment option for the same patient population and target, akin to a newer, more advanced technology challenging an existing approach.

    AI Analysis | Feedback

    Context Therapeutics' main products target significant addressable markets in oncology. For their lead product candidate, onapristone extended release (ONA-XR), a progesterone receptor antagonist for female hormone-dependent cancers: * Analysts estimate a combined peak sales potential of approximately $1 billion for ONA-XR in the U.S. alone. * The broader global progesterone market, which includes therapies for hormone-related conditions and cancers, was valued at approximately USD 1.5 billion in 2024 and is projected to reach USD 4.27 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 12.3% from 2025 to 2033. * Within this market, endometrial cancer protocols are the fastest-growing application, with an estimated CAGR of 11.55% through 2031. For their second product candidate, CLDN6xCD3 bsAb, a bispecific monoclonal antibody targeting Claudin 6 (CLDN6) for gynecologic cancer therapy: * The global bispecific antibodies market, which includes such advanced cancer treatments, was valued at approximately USD 8.65 billion in 2023. This market is projected to reach USD 109.4 billion by 2032, with a CAGR of 34.8% from 2023 to 2032. * More specifically, the global bispecific antibodies in precision oncology market reached US$12.46 billion in 2024 and is expected to reach US$332.77 billion by 2033, growing at a CAGR of 44.05% from 2026 to 2033. North America holds a dominant share, capturing 38.5% of this market in 2025. * CLDN6 is considered a compelling target for solid tumors, particularly in ovarian and testicular cancers. * The global gynecological cancer drugs market, which CLDN6xCD3 bsAb targets, was valued at US$17.8 billion in 2024 and is projected to reach US$24 billion by 2030, with a CAGR of 5.1% from 2024 to 2030. The U.S. market for gynecological cancer drugs was valued at $4.9 billion in 2024. North America dominated the gynecological cancer drugs market revenue in 2025. The ovarian cancer segment within this market is expected to exhibit the fastest growth.

    AI Analysis | Feedback

    Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, is focused on developing novel treatments for solid tumors, particularly female cancers. As the company does not currently have commercialized products, analysts forecast zero revenue for 2026 and 2027. However, projections indicate the potential for significant revenue growth beginning in 2028. The primary drivers of future revenue growth for Context Therapeutics over the next 2-3 years are expected to stem from the advancement and potential commercialization of its pipeline of T-cell engaging bispecific antibodies, alongside strategic partnerships.

    The key expected drivers of future revenue growth include:

    1. Successful Clinical Development and Potential Commercialization of CTIM-76: CTIM-76 is a selective Claudin 6 (CLDN6) x CD3 bispecific antibody being developed for CLDN6-positive tumors. The company initiated a Phase 1 clinical trial for CTIM-76 in January 2025, targeting ovarian, endometrial, and testicular cancers. Initial dose escalation data from this trial are anticipated in the first half of 2026. Positive clinical outcomes and subsequent regulatory approvals would be a significant driver for future revenue.
    2. Advancement and Potential Commercialization of CT-95: CT-95 is an avidity-enhanced mesothelin (MSLN) x CD3 bispecific antibody. Context Therapeutics began a Phase 1 clinical trial for CT-95 in April 2025, focusing on patients with mesothelin-expressing cancers, including ovarian, pancreatic, and mesothelioma. Initial clinical data for CT-95 are expected by mid-2026. Favorable trial results leading to further development and eventual market entry would contribute to revenue growth.
    3. Progress in Clinical Development of CT-202: CT-202 is a Nectin-4 x CD3 bispecific antibody. The company expects to complete the necessary regulatory filings to initiate a first-in-human trial for CT-202 in the second quarter of 2026. Successful progression of this candidate through clinical trials could also open avenues for future revenue generation.
    4. Strategic Partnerships and Licensing Agreements: As a clinical-stage company, Context Therapeutics could generate revenue through collaborations, licensing deals, and milestone payments. Analysts have highlighted the potential for CTIM-76 to attract partnerships due to its unique mechanism. Such agreements could provide upfront payments, research funding, and future royalties on product sales if their pipeline candidates are successfully developed and commercialized by partners.

    AI Analysis | Feedback

    Share Issuance

    • Context Therapeutics expanded its at-the-market (ATM) equity offering program to an aggregate amount of $75 million on October 24, 2025.
    • Prior to this amendment, the company had sold approximately $15 million worth of shares under the previous ATM arrangement.
    • The net proceeds from these offerings are designated for research and development of product candidates, working capital, general corporate purposes, and potentially for acquiring additional assets.

    Outbound Investments

    • Context Therapeutics acquired CT-95 in July 2024.
    • The company in-licensed CT-202 in September 2024.

    Capital Expenditures

    • Context Therapeutics reported capital expenditures of approximately -$17.0 thousand in 2025.
    • Capital expenditures were approximately -$33,948 over the 12 months leading up to Q3 2025.

    Peer Outperformance in Biotechnology

    null
    Share of Biotechnology constituents that CNTX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    14%
    of 454 industry peers · -78.3% return
    3Y
    27%
    of 401 industry peers · -77.1% return
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is CNTX's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 14.1%44.9%95.6% CAH 440% · MCK 381% · COR 186%
    Health Care Services 20 23.0%31.5%12.1% HIMS 319% · RDNT 151% · DGX 79%
    Managed Health Care 8 33.9%-6.4%5.7% OSCR 125% · HQY 43% · ELV 15%
    Health Care Facilities 24 0.9%6.8%4.0% THC 326% · NHC 282% · ENSG 139%
    Health Care Equipment 50 -5.2%-2.8%-16.6% POCI 11350% · UFPT 350% · GKOS 267%
    Pharmaceuticals 62 -10.3%-3.2%-29.9% INDV 1102% · ETON 1006% · LQDA 903%
    Health Care Supplies 12 25.5%-8.2%-36.1% LNTH 322% · HAE 76% · MMSI 20%
    Life Sciences Tools & Services 109 -11.5%-10.1%-63.5% SNWV 2194% · NTRA 251% · MEDP 224%
    Biotechnology ← 364 -20.8%-25.7%-80.0% CELZ 1098% · DNTH 1092% · TRVI 999%
    Health Care Technology 21 -34.8%-58.6%-82.2% SPOK 74% · HSTM 19% · VEEV 3%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1Context Therapeutics Earnings Notes12/16/2025
    Title
    0ARTICLES

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    PCRXPacira BioSciences1.444.0%40.3%
    OPCHOption Care Health4.837.2%-2.5%
    PTCPTC22.335.0%11.6%
    PRMEPrime Medicine0.733.9%15.0%
    PCVXVaxcyte10.326.4%54.7%
    QDELQuidelOrtho0.924.6%-53.0%
    RXORXO4.924.4%130.1%
    PENGPenguin Solutions3.924.3%290.0%
    NVAXNovavax2.121.9%89.7%
    HPKHighPeak Energy1.221.7%101.5%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    AVBPArriVent BioPharma0.8-40.8%-16.8%
    ALMRAlamar Biosciences1.5-26.5%14.9%
    NUAINew Era Energy & Digital0.5-25.4%60.2%
    SHAZSharonAI0.7-25.3%-59.0%
    ANGOAngioDynamics0.5-23.8%-10.3%
    GLASGlass House Brands0.4-22.4%-51.9%
    EOSEEos Energy Enterprises0.9-21.5%-78.0%
    AEHRAehr Test Systems2.7-21.1%319.2%
    YSSYork Space Systems0.9-20.8%-78.8%
    AXTIAXT4.2-20.3%318.7%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MYPSPLAYSTUDIOS0.5740.5%530.4%
    KODKodiak Sciences6.3203.8%257.2%
    DNAGinkgo Bioworks0.891.7%56.4%
    PACBPacific Biosciences of California0.783.5%24.6%
    GRALGRAIL6.181.3%64.2%
    IOVAIovance Biotherapeutics6.679.6%435.5%
    SECZSecuritize2.071.9%12.4%
    MRNAModerna89.564.7%663.0%
    PEverpure51.464.2%130.7%
    PENGPenguin Solutions3.956.9%290.0%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    CTVACorteva8.9-84.3%-80.1%
    LQDALiquidia2.4-59.6%-20.6%
    XNDUXanadu Quantum Technologies1.2-56.6%-66.1%
    QUREuniQure1.5-49.2%-5.6%
    EMATEvolution Metals & Technologies1.0-46.8%-92.3%
    GLASGlass House Brands0.4-46.6%-51.9%
    NKTRNektar Therapeutics1.4-41.7%-2.6%
    AVBPArriVent BioPharma0.8-41.7%-16.8%
    ALHCAlignment Healthcare1.6-40.9%-61.8%
    ABRArbor Realty Trust0.5-40.3%-59.2%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    CNTXVRTXCMNDCNSYCNXUCSBRMedian
    NameContext .Vertex P.Clearmin.Cerenome Conexeu .Champion. 
    Mkt Price0.30510.756.831.943.864.844.35
    Mkt Cap0.0129.60.00.00.10.10.0
    Rev LTM012,587000610
    Op Inc LTM-494,777-9-26-14-1-11
    FCF LTM-413,796-7-24-11-6-9
    FCF 3Y Avg-261,957-5-17--0-5
    CFO LTM-344,293-7-22-11-6-9
    CFO 3Y Avg-232,398-5-16-0-5

    Growth & Margins

    CNTXVRTXCMNDCNSYCNXUCSBRMedian
    NameContext .Vertex P.Clearmin.Cerenome Conexeu .Champion. 
    Rev Chg LTM-10.2%---6.7%8.4%
    Rev Chg 3Y Avg-9.8%---4.9%7.4%
    Rev Chg Q-12.5%---8.8%10.6%
    QoQ Delta Rev Chg LTM-3.0%---2.1%2.6%
    Op Inc Chg LTM-27.2%2,497.9%-53.0%-106.7%--131.0%-53.0%
    Op Inc Chg 3Y Avg-39.7%792.2%-18.0%-26.9%-40.9%-18.0%
    Op Mgn LTM-37.9%----1.5%18.2%
    Op Mgn 3Y Avg-23.9%----0.7%11.6%
    QoQ Delta Op Mgn LTM--0.2%---0.2%-0.0%
    CFO/Rev LTM-34.1%----9.2%12.5%
    CFO/Rev 3Y Avg-19.6%---0.3%9.9%
    FCF/Rev LTM-30.2%----10.1%10.0%
    FCF/Rev 3Y Avg-15.7%----0.4%7.7%

    Valuation

    CNTXVRTXCMNDCNSYCNXUCSBRMedian
    NameContext .Vertex P.Clearmin.Cerenome Conexeu .Champion. 
    Mkt Cap0.0129.60.00.00.10.10.0
    P/S-10.3---1.15.7
    P/Op Inc-0.627.1-0.2-0.5-7.6-72.2-0.5
    P/EBIT-0.625.7-0.2-0.6-7.6-72.2-0.6
    P/E-0.629.4-0.2-0.5-7.6-62.7-0.6
    P/CFO-0.830.2-0.2-0.6-9.9-12.1-0.7
    Total Yield-160.9%3.4%-576.1%-195.9%-13.0%-1.6%-87.0%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg-59.4%1.6%-1,975.5%---1.2%-30.3%
    D/E0.00.01.30.00.00.20.0
    Net D/E-1.5-0.0-10.5-0.6-0.00.1-0.3

    Returns

    CNTXVRTXCMNDCNSYCNXUCSBRMedian
    NameContext .Vertex P.Clearmin.Cerenome Conexeu .Champion. 
    1M Rtn-18.7%-2.0%544.3%-22.1%-13.5%-3.4%-8.4%
    3M Rtn-53.9%5.2%236.5%-51.0%-62.2%-16.8%-33.9%
    6M Rtn-87.9%17.1%-46.6%-51.0%-73.2%-15.8%-48.8%
    12M Rtn-78.5%23.1%-98.2%-51.0%-73.2%-26.2%-62.1%
    3Y Rtn-77.4%41.7%-99.6%-51.0%-73.2%-24.3%-62.1%
    1M Excs Rtn-20.7%-3.6%592.5%-21.7%-12.0%-7.9%-10.0%
    3M Excs Rtn-55.7%2.4%239.1%-55.0%-66.6%-20.6%-37.8%
    6M Excs Rtn-102.3%2.5%-61.8%-65.7%-87.7%-30.4%-63.7%
    12M Excs Rtn-89.1%5.6%-114.5%-66.8%-88.7%-40.9%-77.7%
    3Y Excs Rtn-156.6%-38.6%-186.0%-134.6%-155.8%-106.4%-145.2%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/5/20265/6/20263/23/202611/5/20258/6/20255/7/20253/20/202511/6/20248/7/20245/8/20243/21/202411/9/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-15-9-14-11-10-6-4-19-3-4-7-6
    Operating Income-15-9-14-11-10-6-4-19-3-4-7-6
    Net Income-15-9-13-10-9-5-3-17-2-4-7-6
    EPS-0.15-0.09-0.14-0.10-0.09-0.050.00-0.22-0.04-0.23-0.42-0.37
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-49-44-40-30-38-32-30-33-20-22-25-22
    Operating Income TTM-49-44-40-30-38-32-30-33-20-22-25-22
    Net Income TTM-46-40-36-26-34-28-27-30-19-21-24-21
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-53.4%-69.0%-220.4%43.3%-216.1%-44.6%37.8%-202.7%41.7%42.7%-78.7%-52.7%
    Operating Income Growth-53.4%-69.0%-220.3%43.3%-216.0%-44.6%37.8%-202.6%41.6%42.6%-78.6%-52.7%
    Net Income Growth-64.9%-89.6%-289.6%44.5%-291.5%-24.8%50.6%-197.2%55.0%41.9%-90.3%-52.4%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash4355667784899485102101422
    Total Debt000000000000
    Net Debt / (Cash)-43-54-66-77-83-89-94-85-102-10-14-22
    Cash Flows Quarterly            
    FCF from Operations-7-11-9-7-6-5-5-2-3-4-7-3
    Cash Flows TTM            
    FCF from Operations TTM-34-33-26-22-18-15-15-17-18-20-21-18
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-40.0%-27.2%-44.0%-37.1%-36.4%-21.9%-18.0%-82.4%-16.8%-21.8%-42.4%-42.6%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-32.6%-31.6%-31.6%-26.4%-35.7%-31.3%-31.2%-35.9%-27.2%-31.7%-38.3%-38.0%

    Segment Financials

    Net Income by Segment
    $ Mil202520242023
    Development of clinical and preclinical product candidates for the advancement of therapies to treat-36-27-24
    Total-36-27-24


    Assets by Segment
    $ Mil2023202220212020
    Development of clinical and preclinical product candidates for the advancement of therapies to treat1638510
    Total1638510


    Price Behavior

    Price Behavior
    Market Price$0.30 
    Market Cap ($ Bil)0.0 
    First Trading Date10/20/2021 
    Distance from 52W High-90.9% 
       50 Days200 Days
    DMA Price$0.41$1.55
    DMA Trenddowndown
    Distance from DMA-26.7%-80.4%
     3M1YR
    Volatility84.3%103.2%
    Downside Capture419.83114.08
    Upside Capture-48.24-81.77
    Correlation (SPY)10.5%2.2%
    CNTX Betas & Captures as of 9/30/2026

     1M2M3M6M1Y3Y
    Beta0.320.780.480.260.190.83
    Up Beta5.443.371.11-1.68-0.150.63
    Down Beta1.99-4.73-1.332.011.091.03
    Up Capture-151%-130%-52%-105%-36%13%
    Bmk +ve Days6162766132424
    Stock +ve Days9182853118335
    Down Capture231%427%262%265%78%105%
    Bmk -ve Days16263760120328
    Stock -ve Days13243672128390

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CNTX
    CNTX-73.5%105.5%-0.69-
    Sector ETF (XLV)19.8%15.8%0.943.6%
    Equity (SPY)16.7%13.0%0.912.4%
    Gold (GLD)3.3%29.5%0.113.3%
    Commodities (DBC)44.8%20.9%1.674.3%
    Real Estate (VNQ)4.8%13.8%0.097.1%
    Bitcoin (BTCUSD)-33.8%44.2%-0.814.1%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CNTX
    CNTX-43.4%100.8%-0.10-
    Sector ETF (XLV)7.7%15.2%0.3111.4%
    Equity (SPY)13.9%17.1%0.6214.7%
    Gold (GLD)18.5%18.9%0.790.8%
    Commodities (DBC)10.0%19.6%0.392.8%
    Real Estate (VNQ)1.3%18.8%-0.0411.8%
    Bitcoin (BTCUSD)11.2%52.0%0.398.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CNTX
    CNTX-24.8%100.8%-0.10-
    Sector ETF (XLV)11.0%16.7%0.5311.4%
    Equity (SPY)15.5%17.9%0.7314.7%
    Gold (GLD)11.8%16.4%0.590.8%
    Commodities (DBC)8.2%18.1%0.372.8%
    Real Estate (VNQ)4.5%20.7%0.1811.8%
    Bitcoin (BTCUSD)63.3%66.2%1.038.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date9152026
    Short Interest: Shares Quantity6.9 Mil
    Short Interest: % Change Since 83120266.8%
    Average Daily Volume1.2 Mil
    Days-to-Cover Short Interest5.7 days
    Basic Shares Quantity95.2 Mil
    Short % of Basic Shares7.3%

    Earnings Returns History

    Updated 8/5/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    3/22/2023-7.6%-8.3%-7.6%
    3/23/20221.3%-1.0%-28.6%
    12/2/2021-7.5%9.2%-50.8%
    SUMMARY STATS   
    # Positive110
    # Negative223
    Median Positive1.3%9.2% 
    Median Negative-7.5%-4.6%-28.6%
    Max Positive1.3%9.2% 
    Max Negative-7.6%-8.3%-50.8%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    3/22/2023-7.6%-8.3%-7.6%
    3/23/20221.3%-1.0%-28.6%
    12/2/2021-7.5%9.2%-50.8%
    SUMMARY STATS   
    # Positive110
    # Negative223
    Median Positive1.3%9.2% 
    Median Negative-7.5%-4.6%-28.6%
    Max Positive1.3%9.2% 
    Max Negative-7.6%-8.3%-50.8%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/05/202610-Q
    03/31/202605/06/202610-Q
    12/31/202503/23/202610-K
    09/30/202511/05/202510-Q
    06/30/202508/06/202510-Q
    03/31/202505/07/202510-Q
    12/31/202403/20/202510-K
    09/30/202411/06/202410-Q
    06/30/202408/07/202410-Q
    03/31/202405/08/202410-Q
    12/31/202303/21/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/09/202310-Q
    03/31/202305/10/202310-Q
    12/31/202203/22/202310-K
    09/30/202211/09/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/05/202610-Q
    03/31/202605/06/202610-Q
    12/31/202503/23/202610-K
    09/30/202511/05/202510-Q
    06/30/202508/06/202510-Q
    03/31/202505/07/202510-Q
    12/31/202403/20/202510-K
    09/30/202411/06/202410-Q
    06/30/202408/07/202410-Q
    03/31/202405/08/202410-Q
    12/31/202303/21/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/09/202310-Q
    03/31/202305/10/202310-Q
    12/31/202203/22/202310-K
    09/30/202211/09/202210-Q
    06/30/202208/11/202210-Q
    03/31/202205/11/202210-Q
    12/31/202103/23/202210-K
    09/30/202112/02/202110-Q
    06/30/202110/20/2021424B4
    03/31/202107/23/2021S-1/A

    Insider Activity

    Updated 4/26/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Lehr, Martin AChief Executive OfficerMartin Lehr 2000 TrustBuy61020250.70100,00070,080644,869Form
    2Levit, Alex CChief Legal Officer, Corp. SecDirectBuy61020250.5820,00011,52016,704Form
    3Minai-Azary, Jennifer LynnChief Financial OfficerDirectBuy61020250.6440,01025,48650,966Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Lehr, Martin AChief Executive OfficerMartin Lehr 2000 TrustBuy61020250.70100,00070,080644,869Form
    2Levit, Alex CChief Legal Officer, Corp. SecDirectBuy61020250.5820,00011,52016,704Form
    3Minai-Azary, Jennifer LynnChief Financial OfficerDirectBuy61020250.6440,01025,48650,966Form

    Investor Activity (13F)

    Updated Oct 10, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Avidity Partners Management LP$13.1 Mil2.7%45TRIM -9.2%13F
    MPM Bioimpact LLC$28.0 Mil2.2%41Hold13F
    Octagon Capital Advisors LP$13.8 Mil1.5%29New13F
    Great Point Partners LLC$5.9 Mil1.4%39TRIM -52.2%13F
    Nextech Invest, Ltd.$19.4 Mil1.4%17Hold13F
    TCG Crossover Management, LLC$7.0 Mil0.2%49New13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Octagon Capital Advisors LP$13.8 Mil1.5%29New13F
    TCG Crossover Management, LLC$7.0 Mil0.2%49New13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Great Point Partners LLC$5.9 Mil1.4%39TRIM -52.2%13F
    Avidity Partners Management LP$11.8 Mil2.7%46TRIM -9.2%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    MPM Bioimpact LLC$28.0 Mil2.2%41Hold13F
    Nextech Invest, Ltd.$19.4 Mil1.4%17Hold13F
    Octagon Capital Advisors LP$13.8 Mil1.5%29New13F
    Avidity Partners Management LP$11.8 Mil2.7%46TRIM -9.2%13F
    TCG Crossover Management, LLC$7.0 Mil0.2%49New13F
    Great Point Partners LLC$5.9 Mil1.4%39TRIM -52.2%13F

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 10/9/2026